Sold as Ella. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Ulipristal Acetate (sold as Ella), first approved Aug 13, 2010, with 1 new use approved and 0 published complete response letters.
| Mammogram Pretreatment With Ulipristal AcetateMammography Screening, Breast Density · OHSU Knight Cancer Institute | Phase 2 | Recruiting | Feb 25, 2026 |
| Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency ContraceptionContraception · The University of Hong Kong | Phase 3 | Recruiting | Dec 11, 2024 |
| Disparities in Emergency Contraceptive Metabolism Dictate EfficacyContraceptive Usage · Oregon Health and Science University | Phase 4 | Recruiting | Jan 6, 2023 |
| Aug 13, 2010 | EllaNDA 22474 · New molecular entity | Lab Hra Pharma | 8 | Marketed |
| Feb 13, 2017 | LogiliaANDA 207952 | Teva Pharms USA | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
